Cargando…
P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431058/ http://dx.doi.org/10.1097/01.HS9.0000970432.75766.0c |
| _version_ | 1785091109233360896 |
|---|---|
| author | Bahlis, Nizar J Samaras, Christy Reece, Donna Sebag, Michael Matous, Jeffrey Berdeja, Jesus Shustik, Jesse Schiller, Gary Ganguly, Siddhartha Song, Kevin Seet, Christopher S. Acosta-Rivera, Mirelis Quick, Donald Anz, Bertrand Fonseca, Gustavo Flores, Unicel-Anne Liu, Hongjuan Gentili, Christian Siegel, David |
| author_facet | Bahlis, Nizar J Samaras, Christy Reece, Donna Sebag, Michael Matous, Jeffrey Berdeja, Jesus Shustik, Jesse Schiller, Gary Ganguly, Siddhartha Song, Kevin Seet, Christopher S. Acosta-Rivera, Mirelis Quick, Donald Anz, Bertrand Fonseca, Gustavo Flores, Unicel-Anne Liu, Hongjuan Gentili, Christian Siegel, David |
| author_sort | Bahlis, Nizar J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431058 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310582023-08-17 P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY Bahlis, Nizar J Samaras, Christy Reece, Donna Sebag, Michael Matous, Jeffrey Berdeja, Jesus Shustik, Jesse Schiller, Gary Ganguly, Siddhartha Song, Kevin Seet, Christopher S. Acosta-Rivera, Mirelis Quick, Donald Anz, Bertrand Fonseca, Gustavo Flores, Unicel-Anne Liu, Hongjuan Gentili, Christian Siegel, David Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431058/ http://dx.doi.org/10.1097/01.HS9.0000970432.75766.0c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Bahlis, Nizar J Samaras, Christy Reece, Donna Sebag, Michael Matous, Jeffrey Berdeja, Jesus Shustik, Jesse Schiller, Gary Ganguly, Siddhartha Song, Kevin Seet, Christopher S. Acosta-Rivera, Mirelis Quick, Donald Anz, Bertrand Fonseca, Gustavo Flores, Unicel-Anne Liu, Hongjuan Gentili, Christian Siegel, David P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY |
| title | P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY |
| title_full | P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY |
| title_fullStr | P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY |
| title_full_unstemmed | P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY |
| title_short | P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY |
| title_sort | p882: pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (rrmm): final overall survival analysis of the phase 2 mm-014 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431058/ http://dx.doi.org/10.1097/01.HS9.0000970432.75766.0c |
| work_keys_str_mv | AT bahlisnizarj p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT samaraschristy p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT reecedonna p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT sebagmichael p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT matousjeffrey p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT berdejajesus p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT shustikjesse p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT schillergary p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT gangulysiddhartha p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT songkevin p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT seetchristophers p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT acostariveramirelis p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT quickdonald p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT anzbertrand p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT fonsecagustavo p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT floresunicelanne p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT liuhongjuan p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT gentilichristian p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study AT siegeldavid p882pomalidomidedaratumumabanddexamethasoneafterlenalidomidetreatmentinpatientswithrelapsedorrefractorymultiplemyelomarrmmfinaloverallsurvivalanalysisofthephase2mm014study |